Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc.

Conning Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 291,475 shares of the biopharmaceutical company’s stock after selling 27,106 shares during the quarter. Conning Inc.’s holdings in Gilead Sciences were worth $32,354,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Procyon Advisors LLC lifted its stake in Gilead Sciences by 14.1% in the third quarter. Procyon Advisors LLC now owns 30,204 shares of the biopharmaceutical company’s stock worth $3,353,000 after acquiring an additional 3,721 shares during the last quarter. Lazari Capital Management Inc. acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $202,000. Ashton Thomas Securities LLC purchased a new stake in shares of Gilead Sciences during the 3rd quarter worth $201,000. WealthPlan Investment Management LLC lifted its position in shares of Gilead Sciences by 4.2% during the 3rd quarter. WealthPlan Investment Management LLC now owns 3,238 shares of the biopharmaceutical company’s stock worth $359,000 after purchasing an additional 132 shares during the last quarter. Finally, GWN Securities Inc. grew its stake in shares of Gilead Sciences by 14.3% during the third quarter. GWN Securities Inc. now owns 9,008 shares of the biopharmaceutical company’s stock worth $1,007,000 after purchasing an additional 1,129 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares in the company, valued at $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 130,757 shares of company stock valued at $16,205,752. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 1.9%

GILD opened at $124.07 on Thursday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52 week low of $90.82 and a 52 week high of $128.70. The business’s 50 day moving average is $123.28 and its two-hundred day moving average is $117.89. The firm has a market cap of $153.93 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Rothschild & Co Redburn raised their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Wolfe Research restated an “outperform” rating and set a $150.00 target price on shares of Gilead Sciences in a research note on Monday, December 15th. TD Cowen increased their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, UBS Group began coverage on shares of Gilead Sciences in a report on Wednesday, January 7th. They set a “buy” rating and a $145.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.16.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.